In the present study we aimed to identify the relationship of hyperprolactinemia and polycystic ovarian changes. We retrospectively analyzed the endocrinological and clinical features of 79 hyperprolactinemic patients detected during a 3-year period ending in March 1995. Patients who had hypothyroidism, macroprolactinoma and drug-induced hyperprolactinemia were excluded from the study. Among 61 hyperprolactinemic patients, 41 (67.2%) had ultrasonographically diagnosed polycystic ovaries (PCO). Prolactin levels in the PCO and non-PCO groups were 32.8 +/- 5.8 and 36.7 +/- 5.1 ng/dl, respectively, which was a significant difference (p < 0.05). Hirsutism was associated with hyperprolactinemia in 55.7% of the patients and was found to be more frequent in the PCO (58.8%) than the non-PCO group (41.2%). The mean Ferriman Gallwey scores and both total and free testosterone levels were significantly higher in the PCO group in comparison to the non-PCO group. In addition, a significantly higher body mass index was detected in patients with PCO. We documented a frequent association between hyperprolactinemia and polycystic ovarian changes and suggested that hyperprolactinemia in PCO is most likely related to a pathologic-endocrinologic milieu.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000291850 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The frequency of macroprolactinemia among patients with hyperprolactinemia in a central laboratory of a training and research hospital.
North Clin Istanb
November 2024
Department of Medical Biochemistry, Goztepe Prof. Dr. Suleyman Yalcin Training and Research Hospital, Istanbul, Turkiye.
Objective: Macroprolactinemia is a well-described endocrine disorder, with its results leading to unnecessary tests and overtreatment. However, routine macroprolactin screening is not performed in many laboratories. Routinely used prolactin assays can result in false diagnosis of hyperprolactinemia in patients with no signs and symptoms related to hyperprolactinemia and clinicians should be aware of macroprolactinemia frequency encountered with the method in use.
View Article and Find Full Text PDFAre prolactin levels efficient in predicting a pituitary lesion in patients with hyperprolactinemia?
Endocrine
May 2024
Division of Endocrinology, Diabetology and Metabolism; Department of Medical Sciences, University of Turin, Turin, Italy.
Article Synopsis
- The study aimed to assess the relationship between prolactin (PRL) levels and pituitary abnormalities in a diverse group of patients with hyperprolactinemia, as existing guidelines primarily focus on women.
- Researchers analyzed data from 1,253 patients, identifying 139 who met criteria for inclusion; findings revealed that 76.3% had pituitary disease, with PRL levels showing limited effectiveness in predicting abnormalities, particularly when high PRL values were excluded.
- The conclusion highlights a significant occurrence of pituitary issues in hyperPRL patients, suggesting that MRI scans are essential for diagnosis, emphasizing the need for further research to clarify PRL thresholds for imaging.
Effects of long-term proton pump inhibitor use on sexual hormones and sexual and reproductive health in female patients.
Endocrine
February 2024
Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, Pakistan.
Purpose: Proton pump inhibitors (PPIs) are widely used to treat a range of gastrointestinal diseases around the world. Long-term use of PPIs has been associated to a variety of undesirable effects. Although short-term therapy has been shown to have little or no effect on endocrine hormone in women, however, its long-term safety has received little attention.
View Article and Find Full Text PDFRopinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability.
J Clin Endocrinol Metab
January 2024
Department of Medicine, Columbia University, Vagelos College of P&S, New York, NY 10032, USA.
Context: Treatment of hyperprolactinemia with ergoline dopamine agonists (DAs) can be complicated by intolerance and resistance.
Objective: This study examines the efficacy and tolerability of the nonergot DA ropinirole for the long-term treatment of hyperprolactinemia.
Methods: Twelve hyperprolactinemic women were treated with ropinirole in a 6-month, open-label, dose-escalation trial; 7 of the 12 continued treatment in an extension study for up to 17 months.
What is the optimal prolactin cutoff for predicting the presence of a pituitary adenoma in patients with polycystic ovary syndrome?
Int J Med Sci
April 2023
Department of Neurosurgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Hyperprolactinemia (HPRL) and polycystic ovary syndrome (PCOS) are common causes of infertility in women of reproductive age. A pituitary adenoma (PA) is the most common type of brain tumor that causes HPRL. In the neurosurgical field, the co-existence of PA and PCOS is not common.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!